Adaptation of Aglycosylated Monoclonal Antibodies for Improved Production in Komagataella phaffii,Biotechnology and Bioengineering

当前位置： X-MOL 学术 › Biotechnol. Bioeng. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Adaptation of Aglycosylated Monoclonal Antibodies for Improved Production in Komagataella phaffii
Biotechnology and Bioengineering ( IF 3.5 ) Pub Date : 2024-11-15 , DOI: 10.1002/bit.28878
Yuchen Yang, Neil C. Dalvie, Joseph R. Brady, Christopher A. Naranjo, Timothy Lorgeree, Sergio A. Rodriguez‐Aponte, Ryan S. Johnston, Mary K. Tracey, Carmen M. Elenberger, Eric Lee, Mark Tié, Kerry R. Love, J. Christopher Love

Monoclonal antibodies (mAbs) are a major class of biopharmaceuticals manufactured by well‐established processes using Chinese Hamster Ovary (CHO) cells. Next‐generation biomanufacturing using alternative hosts like Komagataella phaffii could improve the accessibility of these medicines, address broad societal goals for sustainability, and offer financial advantages for accelerated development of new products. Antibodies produced by K. phaffii, however, may manifest unique molecular quality attributes, like host‐dependent, product‐related variants, that could raise potential concerns for clinical use. We demonstrate here conservative modifications to the amino acid sequence of aglycosylated antibodies based on the human IgG1 isotype that minimize product‐related variations when secreted by K. phaffii. A combination of 2–3 changes of amino acids reduced variations across six different aglycosylated versions of commercial mAbs. Expression of a modified sequence of NIST mAb in both K. phaffii and CHO cells showed comparable biophysical properties and molecular variations. These results suggest a path toward the production of high‐quality mAbs that could be expressed interchangeably by either yeast or mammalian cells. Improving molecular designs of proteins to enable a range of manufacturing strategies for well‐characterized biopharmaceuticals could accelerate global accessibility and innovations.

更新日期：2024-11-15

点击分享查看原文

点击收藏

阅读更多本刊新发论文本刊介绍/投稿指南